Compare Lockheed Martin Corporation (LMT) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs Pfizer Inc — how do they compare? Lockheed Martin Corporation trades at $509 (market cap $117.48B), while Pfizer Inc trades at $24.77 (market cap $141.06B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.95%). Which is the better fit depends on your goals.
| LMT | PFE | |
|---|---|---|
Market Cap | $117.48B | $141.06B |
Sector | Industrials | Health |
52-Week High | $676.70 | $28.56 |
52-Week Low | $410.74 | $23.29 |
Enterprise Value | $136.28B | $191.72B |
Dividend Yield | 2.71% | 6.95% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $509.44, showing modest daily gains of 0.13%. The stock faces bearish technical signals with recent earnings misses in Q4 2025 and Q1 2026, though Q3 2025 exceeded expectations. Revenue growth remains steady, reaching $75.05B in 2025, while net margins have compressed to 6.38%. Analyst sentiment is strongly positive with 57% buy ratings and a $614 consensus target, supported by recent contract wins and new product launches like the PAC-3 ACE interceptor.
LMT offers defensive exposure to elevated defense spending with a $194B backlog, but faces execution risks from margin pressure and debt levels. The stock trades at a premium 24.6x P/E with technical weakness near support at $504. Upside depends on Q2 earnings beat and defense budget sustainability amid geopolitical tensions.
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a bullish technical signal despite near-term resistance. The company maintains solid fundamentals with a P/E of 19.12, net income margin of 11.83%, and consistent quarterly earnings beats. Recent news highlights pipeline advancements in oncology and obesity treatments, positioning for a catalyst-rich 2026.
The outlook is cautiously optimistic, supported by a $28.25 analyst price target and a 38.46% buy rating. Key opportunities include dividend stability and pipeline progress, while risks involve patent cliffs and revenue normalization post-COVID. The stock presents a value proposition for income-focused investors amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
